PLA2G4A and colorectal carcinoma: Targeting this pathway, either by pharmacologic inhibition of PLA2G4A with AACOCF3 or by genetic disruption of the PIR-PLA2G4A axis, enhances the efficacy of ferroptosis inducers and suppresses CRC progression.